spacer
home > ebr > autumn 2002 > to clone or not to clone: is politics preventing progress?
PUBLICATIONS
European Biopharmaceutical Review

To Clone or Not to Clone: Is Politics Preventing Progress?

Although US President George W. Bush has made it very clear to the American public that he favours a total ban on human cloning - whether for research or for reproductive purposes - legislation to do so has yet to pass muster in the US Senate. The subject of human cloning and stem cell research is being hotly debated in the US while scientists in other countries, unhampered by the prospect of a governmental ban, are forging ahead. Opponents to cloning fear the ethical and moral implications while proponents are keen to find the scientific answers that may one day lead to cures for Alzheimer's, Parkinson's, juvenile diabetes and a number of other debilitating diseases. Will we run amuck with this intensely powerful technology or learn to use it to our best advantage?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By G. Steven Burrill, CEO of Burrill & Company

G. Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM).
Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G. Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

BioPartnering North America™

26-28 February 2012, Vancouver Convention Centre, Vancouver, BC, Canada

BioPartnering North America 2012 (BPN) in Vancouver, Canada brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up.
More info >>

 
News and Press Releases

APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT

Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.